Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Vasogen-- VAS on TSE -- Ignore unavailable to you. Want to Upgrade?

To: brb who wrote (204)	9/8/1999 10:41:00 AM
From: brb	Read Replies (2) \| Respond to of 377

Finally some news. I don't know that this would justify the run-up in price the last couple of days though. Comments anyone. Wednesday September 8, 9:46 am Eastern Time Company Press Release Terrance H. Gregg Appointed to Vasogen's Board of Directors TORONTO--(BW HealthWire)--Sept. 8, 1999--Vasogen Inc. (TSE:VAS; OTC BB:VSOGF) is pleased to announce, subject to regulatory approval, the appointment of Terrance H. Gregg of Los Angeles, California to its Board of Directors. Mr. Gregg is the President and Chief Operating Officer of MiniMed Inc., a world leader in diabetes management systems. Since being promoted to President and COO in 1996, Mr. Gregg has led MiniMed to a four-fold increase in revenue and a 15-fold increase in market capitalization, currently at $2.7 billion. Prior to joining MiniMed in 1994, Mr. Gregg served in executive positions with Smith & Nephew plc., a diversified health care product company, and Allergan Inc., a leading ophthalmic device and pharmaceutical company. He currently serves as a Health Advisory Board Member of the School of Policy, Planning and Development at the University of Southern California, and as an Advisory Council Member of the San Fernando Valley Economic Research Center at the California State University Northridge. Dr. William Cochrane, Vasogen's Chairman stated: ``We are delighted by Mr. Gregg's decision to join our Board. He brings a valuable combination of healthcare and public market experience that will greatly assist the Company as it enters the United States.' Vasogen is developing proprietary immune modulation therapies to advance the treatment of cardiovascular, autoimmune and related inflammatory diseases. These therapies are designed to target fundamental disease-causing events, providing safe, effective treatment.